默克在美国市场停产关键抗生素Recarbrio,引发超级细菌耐药担忧
STAT+: Merck discontinues a crucial antibiotic despite concerns over superbug resistance
默克上月在美国市场停产重要抗生素Recarbrio,凸显大型药企在公共卫生关键领域投入不足的问题。该药物七年前获批,是一种三种药物联合注射剂,用于在缺乏其他替代治疗选择时,处理成人和儿童的严重感染,如医院或呼吸机相关肺炎,以及复杂的尿路和胃部感染。
原文明确指出默克在美国市场停产关键抗生素Recarbrio,读者可据此理解大型药企在抗感染领域的商业取舍。
![]()
By Ed Silverman
Sept. 28, 2026
Pharmalot Columnist, Senior Writer
Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter.
In an unexpected move, Merck discontinued an important antibiotic from the U.S. market earlier this month, underscoring concerns about the commitment large pharmaceutical companies are willing to make to a field that is crucial to public health.
The drugmaker is no longer supplying Recarbrio, which was approved seven years ago and is used to treat serious infections in adults and children, such as pneumonia that develops from a hospital or ventilator, as well as complicated urinary tract and stomach infections in patients with limited or no alternative treatment options.
The company did not explain its decision, but the antibiotic — a three-drug combination injection — was pegged from the outset as a treatment of last resort by the Food and Drug Administration in hopes of mitigating antibiotic resistance. However, this also limits market and sales potential. Merck did not disclose Recarbrio sales in its regulatory filings.
STAT+ Exclusive Story
Already have an account? Log in

This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
来源:STAT Pharma 医药频道 · statnews.com